Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector with empirical test cases, advancing an AI medicine past early safety evaluations into late-stage efficacy validation. IPF destroys respiratory capacity through severe lung tissue scarring. Patients typically present a median survival rate reaching two to four years post-diagnosis. The AI-identified drug, rentosertib, inhibits the TRAF2- and NCK-interacting kinase to address underlying disease mechanisms when administered orally. A randomised trial evaluated 71 patients across 22 Chinese clinical sites, separating participants into placebo and active treatment cohorts. Investigators administered 30 mg or 60 mg daily doses over a 12-week observation window. Patients assigned to the 60 mg once-daily regimen demonstrated a mean forced vital capacity gain of +98.4 mL, contrasting sharply with the 20.3 mL capacity loss recorded in the placebo group. Safety profiles remained manageable, with adverse events mirroring expected baseline rates across all trial arms. Regulatory authorities at the U.S. Food and Drug Administration (FDA) granted ‘Orphan Drug Designation’ to the asset in February 2023. Algorithmic target prioritisation through multi-omics. The development relies entirely on Pharma.AI, the proprietary computational pipeline operating at Insilico Medicine. The workflow segments into distinct engines handling specific biological and chemical engineering tasks. PandaOmics executes the initial target discovery phase. The system ingests vast biological datasets, processing genomics, clinical trial outcomes, academic literature, and patent intelligence to construct comprehensive biological network models. The algorithms apply causal inference mechanisms to identify novel disease links hidden within the data architecture. PandaOmics isolated TNIK as the primary biological target regarding IPF intervention. The computational system bypassed the receptor tyrosine kinase pathways targeted by existing antifibrotic medications. The software mapped TNIK as a central node regulating fibrosis and inflammation via Wnt, TGF-β, Hippo/YAP-TAZ, JNK, and NF-κB signalling channels. The target selection process integrated a hallmarks-of-aging framework, scoring biological targets based on their implication in multiple aging mechanisms, chronic inflammation, and extracellular matrix remodelling. Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine, said: “IPF is one of the clearest clinical examples of an age-related disease in which fibrosis, chronic inflammation, extracellular matrix remodeling, and cellular senescence intersect. “Rentosertib was not discovered by starting from a conventional target and simply screening more compounds. It came from a biology-first, ageing-informed AI workflow that connected TNIK to fibrotic and inflammatory disease mechanisms, and then used generative chemistry to create a drug candidate with the properties required for clinical development.” Generative molecular engineering execution. Following target selection, the Chemistry42 engine executes generative molecular design. The system departs from traditional high-throughput screening methodologies. Chemistry42 does not search existing compound libraries—instead, the system applies Generative Tensorial Reinforcement Learning to build molecules that physically align with the target protein pocket. This algorithmic engineering process balances structural fit against required pharmacological properties. The computational generation phase synthesised exactly 79 physical molecules to undergo testing. The engineering team selected the 55th iteration to advance into preclinical testing. This targeted generation protocol reduced the timeline from project initiation to preclinical candidate nomination to 18 months. The foundational architecture stems from the 2019 publication of the company’s GENTRL methodology in Nature Biotechnology. The platform establishes reproducible systems regulating molecular generation, avoiding the capital-intensive trial-and-error processes defining standard pharmaceutical chemistry. Validating biological impact through proteomic analysis. Clinical assessment integrates complex proteomic analysis to validate the algorithmically-predicted biological interactions. Insilico Medicine deploys internal proteomic aging-clock frameworks within the IPF trial to capture exploratory geroscience readouts. Chronological-age proteomic clocks – including ProtAge, OrganAgechrono, ipfP3GPT, and PAOPAC – track predicted biological-age changes resulting from the intervention. Researchers apply UK Biobank age-associated trajectories as external comparison datasets, contextualising treatment-responsive proteins against broad population data. Mortality-risk-related proteomic clocks, including PAC and OrganAgemortality, provide orthogonal analytical streams alongside standard clinical endpoints. The clinical teams execute SenMayo and CellAge signature analyses to evaluate senescence and senescence-associated secretory phenotype biology within cellular models. Peer-reviewed research published in Aging and Disease confirmed that pharmacological TNIK inhibition produces senomorphic activity, generating observable reductions in extracellular matrix remodelling indicators. Documenting the computational pipeline. The transition of rentosertib through the clinical pipeline provides a documented, peer-reviewed data trail essential to verifying AI capabilities in life sciences. Nature Biotechnology published the complete discovery-to-clinic progression. The publication details the algorithmic TNIK target prioritisation, the generative chemistry outputs, preclinical efficacy data, and human Phase I pharmacokinetics. The Journal of Medicinal Chemistry published the structural biology validation, detailing the discovery of the novel TNIK inhibitor chemotypes and supplying structural backing via the TNIK kinase domain co-crystal structure. Nature Medicine documented the Phase IIa safety and lung-function data, providing empirical validation of the computational predictions. Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, commented: “Rentosertib is a defining program for Insilico because it represents the full arc of our mission: using AI not only to move faster, but to originate new biology, new chemistry, and new therapeutic opportunities. “This program began with the hypothesis that ageing biology could help identify powerful targets for major diseases. It has now advanced through target discovery, molecular design, preclinical validation, Phase I safety, randomised Phase IIa clinical data, and into Phase III development. For the AI drug discovery field, this is no longer only a speed story—it is a clinical translation story.” Adoption of AI in biopharma requires verifiable data regarding human outcomes. The Phase III trial subjects the generative algorithms to the definitive test of clinical efficacy.

This article introduces a method to render PDF pages as images and use Google DeepMind's Gemma 4 vision-language model for local document parsing. The approach unifies scanned and digital PDFs, eliminating the need for OCR or layout parsers, with flexible visual token budgets and complete code examples.

An anonymous artist exposed bias against AI art by revealing a real Monet painting. Despite controversy, the AI art market is forming, encompassing NFTs and physical installations. A collector spent $72,000 on early AI works. Refik Anadol opened Dataland, the first generative AI museum in Los Angeles. Market data shows digital art sales nearly tripled from 2024 to 2025, but Christie's closed its digital art department. A stock image platform saw an 80% sales jump after allowing AI images. Experts distinguish prompt-generated images from true AI art, which requires deep engagement.

Residents and council say creating affordable housing is more urgent than ‘high-frequency trading’ in nearby City. Campaigners in east London are opposing plans for a datacentre in Brick Lane that they say will worsen the area’s housing crisis and drive long-term residents away.

Savva is a health superapp that pulls your medical records, syncs wearables, and lets you pick from 12+ AI models to explain your health data. Everything lives on your phone with no account or cloud.

AI-generated UGC ad videos cost about $1–$11 each compared to $185 for human creators, but independent studies show they convert worse, and disclosure requirements, platform labeling, and FTC/EU fines can erase the savings. The recommended approach is using AI for cheap hook testing and moving winners to human creators.

A pixel-art evaluation gallery called 'Mustache Perfect' showcases AI failures in rendering Mario's iconic mustache, highlighting ongoing limitations in AI detail reproduction.

TrustAI is an AI tool that runs in the background, observing how your best team members work, and suggests one-click automations across your tools.

The article discusses reshaping the observability stack for the AI era, splitting monitoring into four axes: application (standard OTel stack), infrastructure (GCP metrics into Mimir), CI (post-hoc log pulling to Loki), and LLM (Gemini with Prometheus for real-time cost, Claude Code with BigQuery for SQL aggregation). Emphasizes that data must be shaped before AI can consume it effectively.

Tech giants' investments in AI are undermining their climate neutrality pledges. Google and Amazon's net-zero targets slip away, while Meta scrambles for new business. Other tech news includes US anger at data centers, Trump's crypto earnings, Tesla's sales, South Korea's AI chip boom, China's robotics push, and Britain's AI growth zones.

Solos announced the AirGo A6 smart glasses, lighter at 19g with no cameras, relying on voice AI. They support prescription lenses and come in transparent styles. Privacy accessories for the older V2 model were also introduced.

An analysis of 5,009 Git repositories reveals that mentions of AI tools in commit messages surged from near zero to one in eight by July 2026, while commit message lengths increased significantly for 15% of developers. This signals a new epoch called the Agentocene, but whether AI actually produces more code remains unproven.

A developer transforms his resume website into an AI chat interface, allowing visitors to explore his career through conversation. The site uses Groq for LLM inference with 100-200ms latency at low cost, deliberately throttling token generation for a natural feel. Built with a custom server-side Swift stack, no client-side JavaScript.

Slint, a Rust-based UI toolkit, leverages LSP, hot reload, and a new MCP (Model Context Protocol) to give AI real-time access to the layout tree and runtime interaction, making UI development faster and more intuitive. It supports headless mode for CI and works with multiple languages.

This article explains ten essential probability concepts for machine learning in a clear, intuitive way. It covers random variables, probability distributions, expectation, variance, conditional probability, Bayes' theorem, joint and marginal distributions, likelihood and maximum likelihood estimation, sampling and the law of large numbers, and more. The goal is to demystify how models make decisions under uncertainty.

In June 2026, Google introduced the Open Knowledge Format (OKF), an open specification for how AI agents organise and exchange knowledge. An OKF bundle is just Markdown files, lightweight YAML metadata, and links between concepts, yet it challenges the assumption that every AI application needs embeddings and vector databases.

The article challenges the dominant AI narrative that focuses on frontier labs and heroic inventors. Drawing on historical examples, it argues that long-term economic and corporate success comes from the widespread diffusion of general-purpose technologies, enabled by skill infrastructure and organizational learning. For enterprises, AI transformation requires building internal capabilities, standardizing tools, and creating mechanisms for shared learning.

Heyalo is a real-time AI sales intelligence tool that surfaces live signals and answers during calls, then auto-generates recaps and follow-ups after hang-up. It operates through the browser without a bot joining, integrates with major meeting platforms, and offers free and Pro tiers.

The real history of knowledge distillation predates the famous 2015 Hinton paper by nearly a decade, rooted in 2006 work on compression as mimicry. This article reviews three foundational papers that shaped the field.

Companies are shifting budgets from employees to AI tokens, but early data shows this trade-off isn't yielding expected returns. Gartner found no correlation between layoffs and improved ROI, while firms like Klarna are rehiring humans after AI-led quality declines.

Money Magician is an AI-powered financial co-pilot designed for founders and creators, offering smart financial assistance beyond traditional budgeting apps.

ABC Australia plans to trial generative AI for news production, raising questions about ethics and quality, while also offering efficiency gains and innovation opportunities. The news industry must balance technology with professional gatekeeping amid a trust crisis.

Prevail is an open-source AI system designed for personal life management, focusing on helping users optimize their daily lives rather than work. It aims to be an AI assistant for life, not your job.

Brianni is an AI chat app integrating GPT, Claude, and Gemini with a provable claim of operator blindness. Conversations are encrypted with user-derived keys, and plaintext only exists inside AWS Nitro Enclaves with verifiable code measurements. Users can independently verify the system by reproducing the enclave build and comparing the PCR0 hash.

Enterprise AI spend and outcomes are diverging. Federal agencies doubled AI use from 2023 to 2024, but pricing remains a challenge. This article offers four strategies: reversible transformation decisions, evidence-based negotiation leverage, short-cycle commercial commitments, and independent accountability for SI and vendor productivity.

L’Oreal, Nestle, Mondelez and other consumer goods companies are using AI to accelerate product development, optimize formulations, and address supply chain challenges. L’Oreal uses AI to predict molecular effects, quadrupling formulation speed; Mondelez leverages AI to generate and evaluate cookie recipes, with 60% of AI-produced recipes performing better on nutrition, sustainability, and cost; Nestle employs AI to screen natural color alternatives and develop high-barrier packaging materials. These technologies are not replacing human teams but speeding up R&D processes.

Graphenium is an open-source local trust layer that gives AI coding agents a structured memory of the codebase. It builds a trusted dependency graph, helps agents plan edits, and verifies changes after editing. Fully local, supports multiple languages.

AI coding agents are leaving configuration files, logs, and helper artifacts in codebases that leak secrets via npm packages, GitHub, and web assets. Research shows widespread exposure, with recommendations for mitigation.

PixelGlass is an AI agent that builds unique Ghost blog themes from simple descriptions, with no lock-in or subscription.

FaultFixer is a tool that adds self-healing capabilities to websites and apps with a single line of code. It uses AI to detect front-end and back-end errors, diagnose root causes, and deliver fixes directly to your AI coding tools via MCP. Currently free, with paid plans possibly introduced later after notice.